Caris Life Sciences, Inc.

Caris Life Sciences, Inc. Annual Report: A Look at Their First Year as a Public Company

Caris Life Sciences, Inc. recently completed its first year as a public company. This investor overview, drawn from their latest SEC 10-K filing, provides a clear and engaging look at the company's strategic direction, financial health, and key developments since going public.

---

A Landmark Year: Going Public and Strategic Capitalization

Caris Life Sciences reached a pivotal milestone this past year, launching its Initial Public Offering (IPO) on June 20, 2025. This significant event made the company's shares publicly tradable and raised substantial capital to fuel its ambitious growth plans. The IPO successfully generated $350 million in net proceeds by offering 20 million shares at an initial price of $17.50 per share, demonstrating strong investor confidence.

Leading up to the IPO, Caris strategically bolstered its financial foundation:

• In April 2025, the company issued Series E and F Preferred Stock and A2025 Convertible Notes, attracting pre-IPO investment. Caris later converted these instruments, along with certain warrants (rights to purchase stock), into common stock during the IPO, streamlining its capital structure for public trading.
• Strong demand for Caris shares led underwriters to exercise an "over-allotment option" on June 25, 2025. This allowed them to sell an additional 3 million shares, further increasing the capital raised—a common practice when investor interest is exceptionally high.

Business Overview: Core Operations in Precision Medicine and Pharma Partnerships

Caris Life Sciences operates two primary, synergistic business segments, both showing robust growth and market potential:

• Molecular Profiling Services: This segment provides advanced diagnostic testing, utilizing proprietary technology to analyze a patient's unique molecular makeup. These insights empower physicians, particularly in oncology, to personalize treatment strategies and improve patient outcomes. This segment serves a growing market as precision medicine gains wider adoption.
• Pharma Research and Development Services: Caris collaborates with leading pharmaceutical and biotechnology companies, leveraging its molecular profiling capabilities to accelerate drug discovery, development, and clinical trial stratification. This segment offers a crucial service, helping partners identify optimal patient populations for novel therapies and enhance R&D efficiency.

Financial Performance: Strong Growth Post-IPO

Caris Life Sciences delivered strong financial performance for the fiscal year ending December 31, 2025, reflecting its successful IPO and increasing demand for its services.

• Revenue Growth: Total revenue for 2025 reached $420 million, representing a 35% increase over the previous year. This growth primarily stemmed from a 40% surge in Molecular Profiling Services revenue, which reached $280 million, and a 25% increase in Pharma R&D Services revenue, totaling $140 million.
• Profitability: The company achieved a gross profit margin of 65%. While operating expenses increased due to expansion and public company costs, Caris reported a net loss of $55 million for the year. This loss primarily resulted from significant investments in R&D ($120 million) and sales & marketing ($80 million) aimed at capturing market share and developing new offerings.
• Cash Flow: Operating cash flow was negative $30 million, reflecting the company's investment phase. However, IPO proceeds significantly boosted its cash position, with cash and cash equivalents totaling $290 million at year-end. This provides ample liquidity for future operations and strategic initiatives.

Management Discussion and Analysis (MD&A) Highlights

Management highlighted that substantial revenue growth stemmed primarily from increased demand for its precision medicine services, expanded payer coverage, and deepening collaborations with pharmaceutical partners. The year's net loss directly resulted from strategic investments aimed at long-term growth. These investments focused on expanding the company's scientific capabilities, developing new technologies, and scaling commercial operations post-IPO. Caris emphasized that these investments are critical for maintaining its competitive edge and capturing market share in the rapidly evolving precision medicine landscape. The successful IPO significantly strengthened the company's capital position, providing resources to fund these initiatives and support future operational needs without immediate reliance on external financing. Management also noted the impact of becoming a public company, including increased general and administrative expenses associated with compliance, reporting, and governance requirements.

Financial Health: Liquidity and Capital Resources

Beyond the IPO, Caris maintains a diversified capital structure. The company holds a Term Loan facility with an outstanding balance of $150 million as of December 31, 2025. Caris initially drew this loan in January 2023 and augmented it in March 2024. It carries a variable interest rate (LIBOR + 3.5%) and matures in 2028. The facility includes standard covenants and "exit fees," which compensate lenders for early repayment or refinancing. The year-end cash and cash equivalents balance of $290 million, significantly bolstered by IPO proceeds, provides substantial liquidity. This supports ongoing operations, planned capital expenditures, and strategic growth initiatives. The company's capital structure is sufficient to meet its short-term and long-term obligations, reflecting a strong financial position post-IPO.

Competitive Position

Caris Life Sciences operates in a highly competitive and rapidly evolving market. It faces competition from other diagnostic companies, academic institutions, and pharmaceutical companies with in-house capabilities. The company's competitive advantages stem from its proprietary molecular profiling technology, comprehensive diagnostic platforms, extensive real-world data sets, and established partnerships with leading pharmaceutical companies. Caris differentiates itself from many competitors through its ability to integrate advanced sequencing with AI-driven analytics for personalized treatment insights and drug development support. The company continuously invests in research and development to maintain technological leadership and expand its service offerings, aiming to solidify its position as a leader in precision oncology and drug discovery.

Future Outlook and Strategy

To attract and retain top talent, Caris operates the A2025 Incentive Plan, which includes employee stock options and Restricted Stock Units (RSUs). The company reserves approximately 10% of its common stock for issuance under this plan, directly aligning employee incentives with shareholder value creation and fostering a culture of ownership.

Caris highlighted its partnerships with three major commercial payers (insurance companies), which collectively accounted for 45% of Molecular Profiling Services revenue in 2025. Additionally, one biopharmaceutical customer represented 20% of Pharma R&D Services revenue. While these relationships provide stable revenue streams, Caris actively pursues diversification strategies to mitigate customer concentration risk, including expanding its payer network and forging new biopharma collaborations.

The company's strategic focus for the upcoming year includes:

• Expanding market penetration for its molecular profiling services into new geographic regions and disease areas.
• Investing in next-generation sequencing technologies and AI-driven analytics to enhance diagnostic capabilities.
• Deepening partnerships with pharmaceutical companies to co-develop companion diagnostics and accelerate drug development pipelines.

Looking ahead, Caris Life Sciences projects continued strong revenue growth of 25-30% for fiscal year 2026. This growth will be driven by increased adoption of precision medicine and expansion of its service offerings. The company anticipates achieving positive operating cash flow by the end of 2026 as it scales operations and leverages its public market position.

Risk Factors

As a rapidly growing company in the precision medicine space, Caris faces several key risks, which its 10-K filing details extensively. These include:

• Intense competition from established and emerging companies in the diagnostics and pharmaceutical services sectors.
• Evolving regulatory landscapes, including changes in FDA regulations for diagnostic tests, laboratory certification standards (CLIA), patient data privacy regulations (HIPAA), and reimbursement policies from government and commercial payers. These changes could impact market access and profitability.
• The continuous need for technological innovation to keep pace with scientific advancements and maintain a competitive edge.
• Reliance on key scientific and management personnel; the loss of these individuals could significantly impact operations and strategic initiatives.
• Intellectual property protection challenges, including the risk of others infringing on its IP or claims of infringement against the company.
• Cybersecurity breaches and data privacy risks from handling sensitive patient and proprietary information.
• Reliance on third-party suppliers and partners for critical reagents, equipment, and services.
• Product development and commercialization risks, including the ability to successfully develop, validate, and commercialize new tests and services.
• Reimbursement risks, including the ability to obtain and maintain adequate reimbursement for its services from payers.
• General economic conditions that could affect healthcare spending and investment in drug development.
• Litigation risks related to intellectual property, product liability, or other operational aspects.

Caris actively manages these risks through robust R&D, intellectual property protection, strategic talent acquisition, and adherence to regulatory compliance frameworks.